Sandra Lithgow
Internal Medicine · Bronx, NYNPI 1205933033
Payments from drug & device makers
Across 205 payments — averaging $19.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Pfizer$742
- Novo Nordisk$703
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$219
- Exact Sciences$178
- AstraZeneca$126
- plus $735 from 18 others
What the payments were for
- Food & beverage$3,96798%
- Education$652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 65 | $1,329 |
| Pfizer | 42 | $742 |
| Novo Nordisk | 32 | $703 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $219 |
| Exact Sciences | 6 | $178 |
| AstraZeneca | 8 | $126 |
| GSK | 7 | $125 |
| Merck | 6 | $120 |
| Amgen(2 entities) | 3 | $63 |
| Novartis | 3 | $53 |
| Kowa Pharmaceuticals America, Inc. | 4 | $52 |
| Sanofi Pasteur Inc. | 3 | $42 |
| Boehringer Ingelheim | 2 | $41 |
| Phadia US Inc. | 2 | $36 |
| CSL Behring | 1 | $30 |
| Genentech USA, Inc. | 2 | $29 |
| Antares Pharma, Inc. | 1 | $27 |
| Halozyme Inc | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Seqirus USA Inc | 1 | $21 |
| Medtronic | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $10 |
How this compares
$4,032 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 64 | $43,020 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,720 |
| Rosuvastatin Calcium | 161 | $3,271 |
| SynthroidLevothyroxine Sodium | 39 | $2,632 |
| Atorvastatin Calcium | 91 | $1,446 |
| PaxlovidNirmatrelvir/Ritonavir | 21 | $1,429 |
| Levothyroxine Sodium | 94 | $1,397 |
| Losartan Potassium | 69 | $1,195 |
| Gabapentin | 27 | $1,160 |
| Mirtazapine | 14 | $1,040 |
| Potassium Citrate ErPotassium Citrate | 12 | $946 |
| Olmesartan Medoxomil | 24 | $883 |
| Pantoprazole Sodium | 39 | $817 |
| Valsartan | 39 | $779 |
| Amlodipine Besylate | 76 | $778 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $742 | $44,45085 claims |
| GSKAnoro Ellipta | $125 | $5,72012 claims |
| AbbVieSynthroid | $1,329 | $2,63239 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Bronx
- Benjamin GartrellBronx$6.3M
- David SteinBronx$2.4M
- Haiying ChengBronx$1.7M
- Jason LeiderBronx$1.4M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.